Correction of hyperphosphatemia in a patient with end-stage chronic kidney disease and a complex case of anemia. A clinical case
- Authors: Fomin V.V.1
-
Affiliations:
- Sechenov First Moscow State Medical University (Sechenov University)
- Issue: Vol 26, No 1 (2024): Cardiology and Nephrology
- Pages: 62-66
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/256830
- DOI: https://doi.org/10.26442/20751753.2024.1.202777
- ID: 256830
Cite item
Full Text
Abstract
Iron supplements and/or blood transfusions in combination with recombinant human erythropoietin injections are routinely used to correct renal anemia, which is a common complication of end-stage renal disease. However, massive blood transfusions and inadequate intravenous iron supplementation can lead to iron overload syndrome, and anemia is not always nephrogenic. A rare clinical case of a patient with end-stage chronic kidney disease with complex genesis of anemia, who is on hemodialysis, is presented. The case is interesting because the prescription of first-line drugs was life-threatening in nature, and sevelamer was the drug chosen for the correction of mineral-bone disorders.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Victor V. Fomin
Sechenov First Moscow State Medical University (Sechenov University)
Author for correspondence.
Email: fomin_v_v_1@staff.sechenov.ru
ORCID iD: 0000-0002-2682-4417
D. Sci. (Med.), Prof., Corr. Memb. RAS
Russian Federation, MoscowReferences
- Hamer RA, El Nahas AM. The burden of chronic kidney disease. BMJ. 2006;332(7541):563-4. doi: 10.1136/bmj.332.7541.563
- Rodriguez M, Felsenfeld AJ. PTH, FGF-23 and early CKD. Nephrol Dial Transplant. 2008;23(11):3391-3. doi: 10.1093/ndt/gfn438
- Qunibi WY. Cardiovascular calcification in nondialyzed patients with chronic kidney disease. Semin Dial. 2007;20(2):134-8. doi: 10.1111/j.1525-139X.2007.00260.x
- Coen G, Pierantozzi A, Spizzichino D, et al. Risk factors of one year increment of coronary calcifications and survival in hemodialysis patients. BMC Nephrol. 2010;11(10):1-9. doi: 10.1186/1471-2369-11-10
- Волгина Г., Селезнев Д., Балкарова О., Ловчинский Е. Внекостная кальцификация у пациентов с хронической болезнью почек. Врач. 2012;(7):2-8 [Volgina G, Seleznev D, Balkarova O, Lovchinsky E. Extraosseous calcification in patients with chronic kidney disease. Vrach. 2012;(7):2-8 (in Russian)].
- Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol. 2004;15(12):2959-64. doi: 10.1097/01.ASN.0000145894.57533.C4
- Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987;316(2):73-8. doi: 10.1056/NEJM198701083160203
- Carter RA, Hawkins JB, Robinson BH. Iron metabolism in the anaemia of chronic renal failure. Effects of dialysis and of parenteral iron. Br Med J. 1969;3(5664):206-10. doi: 10.1136/bmj.3.5664.206
- Milman N. Iron absorption measured by whole body counting and the relation to marrow iron stores in chronic uremia. Clin Nephrol. 1982;17(2):77-81.
- Kalantar-Zadeh K, Rodriguez RA, Humphreys MH. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant. 2004;19(1):141-9. doi: 10.1093/ndt/gfg493
- Fishbane S, Pollack S, Feldman HI, Joffe MM. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988–2004. Clin J Am Soc Nephrol. 2009;4(1):57-61. doi: 10.2215/CJN.01670408
- Kuragano T, Shimonaka Y, Kida A, et al. Determinants of hepcidin in patients on maintenance hemodialysis: role of inflammation. Am J Nephrol. 2010;31(6):534-40. doi: 10.1159/000312381
- Young B, Zaritsky J. Hepcidin for clinicians. Clin J Am Soc Nephrol. 2009;4(8):1384-7. doi: 10.2215/CJN.02190309
- Zaritsky J, Young B, Wang HJ, et al. Hepcidin – a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1051-6. doi: 10.2215/CJN.05931108
- Волошина Н.Б., Осипенко М.Ф., Литвинова Н.В., Волошин А.Н. Гемохроматоз – современное состояние проблемы. Терапевтический архив. 2018;90(3):107-12 [Voloshinà NB, Osipenko MF, Litvinova NV, Voloshin A.N. Hemochromatosis – modern condition of the problem. Terapevticheskii Arkhiv (Ter. Arkh.). 2018;90(3):107-12 (in Russian)]. doi: 10.26442/terarkh2018903107-112
- Ganz T, Nemeth E. Iron Balance and the Role of Hepcidin in Chronic Kidney Disease. Semin Nephrol. 2016;36(2):87-93. doi: 10.1016/j.semnephrol.2016.02.001
- KDOQI; National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006;47(5 Suppl. 3):S11-145. doi: 10.1053/j.ajkd.2006.03.010. Erratum in: Am J Kidney Dis. 2006;48(3):518.
- Macginley R, Walker R, Irving M. KHA-CARI Guideline: use of iron in chronic kidney disease patients. Nephrology (Carlton). 2013;18(12):747-9. doi: 10.1111/nep.12139
- Macdougall IC, Bircher AJ, Eckardt KU, et al; Conference Participants. Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 2016;89(1):28-39. doi: 10.1016/j.kint.2015.10.002
- Charytan C, Qunibi W, Bailie GR; Venofer Clinical Studies Group. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract. 2005;100(3):c55-62. doi: 10.1159/000085049
- KDIGO. KDIGO Clinical Practice Guideline for Anemia In Chronic Kidney Disease. Kidney Int Suppl. 2012;2(4):279-335.
- Pitts TO, Barbour GL. Hemosiderosis secondary to chronic parenteral iron therapy in maintenance hemodialysis patients. Nephron. 1978;22(4-6):316-21. doi: 10.1159/000181469
- Brown MC, Gaffney D, Gemmell C, et al. Hemochromatosis gene mutations and treatment of anemia in patients on hemodialysis. Hemodial Int. 2009;13(4):460-6. doi: 10.1111/j.1542-4758.2009.00378.x
- Almasi M, Hajisalimi B. Comparing the effect of sevelamer carbonate versus sevelamer hydrochloride on blood level cholesterol, triglyceride and uric acid in patients undergoing maintenance hemodialysis. J Parathyr Dis. 2020;8:e11173.
- Covic A, Ketteler M, Rastogi A, et al. Efficacy and Safety of Sucroferric Oxyhydroxide (Velphoro®; Pa21) and Sevelamer Carbonate in Haemodialysis Patients With or Without Diabetes: A Post Hoc Analysis of a Phase 3 Study. Conference: ERA-EDTA. 2014.
- Nerild HH, Brønden A, Haddouchi AE, et al. Elucidating the glucose-lowering effect of the bile acid sequestrant sevelamer. Diabetes Obes Metab. 2024;26(4):1252-63. doi: 10.1111/dom.15421
- Shakeri H, Panarelli NC. Patterns of gastrointestinal injury in patients with chronic kidney disease: Comparison of cases with and without sevelamer crystals. Histopathology. 2024;84(4):624-32. doi: 10.1111/his.15104